Clarissa Baldotto

Clarissa Baldotto

Auto-generated profile, based on publicly available information

Clarissa Baldotto

Instituto D’Or de Pesquisa e Ensino - Department of Clinical Oncology , Rio de Janeiro

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2013 in Journal of Cancer Research
Verified
Journal Article
Open access
PDF file
TRTomas Reinert
Tomas Reinert
CBClarissa Serodio da Rocha Baldotto
Clarissa Serodio da Rocha Baldotto
FNFrederico Arthur Pereira Nunes
Frederico Arthur Pereira Nunes
ASAdriana Alves de Souza Scheliga
Adriana Alves de Souza Scheliga
Bleomycin is a chemotherapeutic agent commonly used to treat curable diseases such as germinative tumors and Hodgkin’s lymphoma. The major limitation of bleomycin therapy is pulmonary toxicity, which can be life threatening in up to 10% of patients receiving the drug. The mechanism of bleomycin-induced pneumonitis (BIP) involves oxidative damage, relative deficiency of the deactivating enzyme bleomycin hydrolase, genetic susceptibility, and the elaboration of inflammatory cytokines. Ultimately, BIP can progress to lung fibrosis. The diagnosis of BIP is established by the combination of systemic symptoms, radiological and histological findings, and respiratory function tests abnormalities, while other disorders should be excluded. Although the diagnosis and pathophysiology of this disease have been better characterized over the past few years, there is no effective therapy for the disease. In general, the clinical picture is extremely complex. A greater understanding of the BIP pathogenesis may lead to the development of new agents capable of preventing or even treating the injury already present. Physicians who prescribe bleomycin must be aware of the potential pulmonary toxicity, especially in the presence of risk factors. This review will focus on BIP, mainly regarding recent advances and perspectives in diagnosis and treatment.

1 February 2018 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
PDF file
LALuiz Henrique Araujo
Luiz Henrique Araujo
CBClarissa Baldotto
Clarissa Baldotto
GJGilberto de Castro Jr
Gilberto de Castro Jr
AKArtur Katz
Artur Katz
CFCarlos Gil Ferreira
Carlos Gil Ferreira
CBCarlos Barrios
Carlos Barrios
Lung cancer is one of the most incident types of cancer and a leading cause of cancer mortality in Brazil. We reviewed the current status of lung cancer by searching relevant data on prevention, diagnosis, and treatment in the country. This review highlights several issues that need to be addressed, including smoking control, patient lack of awareness, late diagnosis, and disparities in the access to cancer health care facilities in Brazil. We propose strategies to help overcome these limitations and challenge health care providers, as well as the society and governmental representatives, to work together and to take a step forward in fighting lung cancer.

2 June 2025 in Annals of Oncology
Verified
Journal Article
Open access
FMFilippo de Marinis
Filippo de Marinis
TKT.M. Kim
T.M. Kim
LBL. Bonanno
L. Bonanno
SCS. Cheng
S. Cheng
SKS.-W. Kim
S.-W. Kim
JAJin Seok Ahn
Jin Seok Ahn
MET-based resistance following osimertinib treatment for epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC) is common. We report the primary analysis of the phase II SAVANNAH study (NCT03778229) evaluating savolitinib plus osimertinib in this setting. Patients had EGFR-mutated, advanced NSCLC with MET overexpression and/or amplification. MET cut-offs were initially MET immunohistochemistry (IHC)3+/≥50% (3+ intensity in ≥50% of tumor cells) and/or FISH5+ (≥5 MET gene copies or MET/chromosome 7 centromere ratio ≥2), and increased to MET IHC3+/≥90% and/or FISH10+ after a preliminary analysis. Patients received oral savolitinib [300 mg twice daily (b.i.d.) or once daily (o.d.), or 600 mg o.d.] plus osimertinib 80 mg o.d., or savolitinib 300 mg b.i.d. plus placebo. A primary endpoint was investigator-assessed objective response rate (ORR) in patients with progression on first-line osimertinib and MET IHC3+/≥90% and/or FISH10+ status receiving savolitinib 300 mg b.i.d. plus osimertinib (primary efficacy population). Safety was analyzed in all patients receiving savolitinib plus osimertinib. Of the 365 patients treated, 341 received savolitinib plus osimertinib, with 80 of these included in the primary efficacy population. Investigator-assessed confirmed ORR in the primary efficacy population was 56.3% [95% confidence interval (CI) 44.7% to 67.3%]; the median duration of response (mDoR) was 7.1 months (95% CI 5.6-9.6 months); the median progression-free survival (PFS) was 7.4 months (95% CI 5.5-7.6 months). Blinded independent central review was consistent: confirmed ORR 55.0% (95% CI 43.5% to 66.2%); mDoR 9.9 months (95% CI 6.0-13.7 months); median PFS 7.5 months (95% CI 6.4-11.3 months). The most common any grade adverse events in patients receiving savolitinib plus osimertinib were peripheral edema (46.0%), nausea (40.5%), and diarrhea (23.2%). Savolitinib 300 mg b.i.d. plus osimertinib demonstrated high, clinically meaningful and durable responses in patients with EGFR-mutated, advanced NSCLC with MET IHC3+/≥90% and/or FISH10+ status following progression on first-line osimertinib. The combination was well tolerated and may provide a new oral targeted treatment approach in this setting.

23 July 2009 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
NINeli Muraki Ishikawa
Neli Muraki Ishikawa
LTLuiz Claudio Santos Thuler
Luiz Claudio Santos Thuler
AGAlessandra Grasso Giglio
Alessandra Grasso Giglio
CBClarissa Seródio da Rocha Baldotto
Clarissa Seródio da Rocha Baldotto
CACarlos José Coelho de Andrade
Carlos José Coelho de Andrade
SDSophie Françoise Mauricette Derchain
Sophie Françoise Mauricette Derchain

1 January 2020 in Clinics
Verified
Journal Article
Open access
CBClarissa Baldotto
Clarissa Baldotto
AGAna Gelatti
Ana Gelatti
AAArthur Accioly
Arthur Accioly
CMClarissa Mathias
Clarissa Mathias
EMEldsamira Mascarenhas
Eldsamira Mascarenhas
GCGilberto de Castro-Júnior
Gilberto de Castro-Júnior
New cases of the novel coronavirus disease 2019 (COVID-19), also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continue to rise worldwide following the declaration of a pandemic by the World Health Organization (WHO). The current ...

10 February 2012 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
CBClarissa Seródio Baldotto
Clarissa Seródio Baldotto
ECEduardo Henrique Cronemberger
Eduardo Henrique Cronemberger
PBPaulo de Biasi
Paulo de Biasi
MZMauro Zamboni
Mauro Zamboni
ASAureliano Sousa
Aureliano Sousa
CFCarlos Gil Ferreira
Carlos Gil Ferreira